ECPella 5+ in Patients With Cardiogenic Shock: Potential for Improved Outcomes
Authors' conclusion
These findings suggest that Impella 5+ may further improve outcomes of ECPella.
Study context
- Population
- Patients with cardiogenic shock treated with veno-arterial extracorporeal membrane oxygenation (VA-ECMO) and Impella (ECPella)24 articles
- Exposure
- ECPella 5+ vs all ECPella combinations
- Outcome
- Mortality
Methodological detailsdescriptive, Cohort treated between January 2022 and May 2023, 84 studies published in Pubmed between January 2017 and October 2023 evaluated
- Descriptive
- Cohort treated between January 2022 and May 2023
- 84 studies published in Pubmed between January 2017 and October 2023 evaluated
Main finding
As reported in the abstract
Mortality (published studies)
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| Mortality, single-centre contemporary cohort | Our patient 30% |
Mortality, single-centre contemporary cohort
- Consistent with the published ECPella 5+ mortality
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
ECPella 5+ in Patients With Cardiogenic Shock: Potential for Improved Outcomes. J Cardiothorac Vasc Anesth. Published 12 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →